Changing role of the oestrogen receptor in the life and death of breast cancer cells

Breast

Volumn 12, Issue 6, 2003, Pages 432-441

  Jordan, V Craig ^a   Osipo, C ^a   MacGregor Schafer, J ^a   Fox, J E ^a   Cheng, Dong ^a   Liu, Hong ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; CASPASE 8; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; FAS ANTIGEN; FAS LIGAND; FULVESTRANT; GOSERELIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LETROZOLE; LEUPRORELIN; MESSENGER RNA; ONCOPROTEIN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; ARTICLE; BLOOD CLOTTING DISORDER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER INCIDENCE; CELL DEATH; CELL SURVIVAL; CHRONIC DISEASE; CLINICAL TRIAL; DATA ANALYSIS; DRUG EFFICACY; DRUG USE; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; ESTROGEN SYNTHESIS; FEMALE; GROWTH STIMULATION; HIGH RISK POPULATION; HUMAN; LIFESPAN; MAINTENANCE THERAPY; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN TARGETING; SUPERSENSITIVITY; TREATMENT PLANNING; TUMOR GROWTH;

EID: 0344760841     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(03)00149-8     Document Type: Article

References (74)

1. Beatson G T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896; 2: 104-107.
2. Jensen E V, Jacobson H I. Basic guides to the mechanism of estrogen action. Recent Prog Horm Res 1962; 18: 387-414.
3. Toft D, Gorski J. A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization. Proc Natl Acad Sci USA 1966; 55: 1574-1581.
4. Jensen E V, Block G E, Smith S, Kyser K, DeSombre E R. Estrogen receptors and breast cancer response to adrenalectomy. Natl Cancer Inst Monogr 1971; 34: 55-70.
5. McGuire W L, Carbone P P, Vollmer E P. Estrogen receptors in human breast cancer. New York: Raven Press, 1975.
6. Herbst A L, Griffiths C T, Kistner R W. Clomiphene citrate (NSC-35770) in disseminated mammary carcinoma. Cancer Chemother Rep 1964; 43: 39-41.
7. Lerner L J. The first non-steroidal antiestrogen-MER 25. Nonsteroidal Antioestrogens: Molecular Pharmacology and Antitumour Activity. Sydney: Academic Press, 1981: 1-6.
8. Legha S S, Slavik M, Carter S K. Nafoxidine - an antiestrogen for the treatment of breast cancer. Cancer 1976; 38: 1535-1541.
9. Harper M J, Walpole A L. A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J Reprod Fertil 1967; 13: 101-119.
10. Klopper A, Hall M. New synthetic agent for the induction of ovulation. Preliminary trial in women. Br Med J 1971; 1: 152-154.
11. Williamson J G, Ellis J D. The induction of ovulation by tamoxifen. J Obstet Gynaecol Br Commonw 1973; 80: 844-847.
12. Lunan C B, Klopper A. Antioestrogens: a review. Clin Endocrinol 1975; 4: 551-572.
13. Cole M P, Jones C T, Todd I D. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46474. Br J Cancer 1971; 25: 270-275.
14. Jordan V C, Koerner S. Tamoxifen (ICI 46, 474) and the human carcinoma 8S oestrogen receptor. Eur J Cancer 1975; 11: 205-206.
15. Jordan V C. Effect of tamoxifen (ICI 46, 474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer 1976; 12: 419-424.
16. Jordan V C, Jaspan T. Tamoxifen as an antitumour agent: oestrogen binding as a predictive test for tumour response. J Endocrinol 1976; 68: 453-460.
17. Kiang D T, Kennedy B J. Tamoxifen (antiestrogen) therapy in advanced breast cancer. Ann Intern Med 1977; 87: 687-690.
18. Jordan V C, Dix C J, Allen K E. The effectiveness of long term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer. Adjuvant Ther Cancer 1979; 2: 19-26.
19. Jordan V C, Allen K E. Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 1980; 16: 239-251.
20. Jordan V C. The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole. Breast Cancer Res Treat 1988; 11: 197-209.
21. Jordan V C. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discovery 2003; 2: 205-213.
22. Osborne C K. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339: 1609-1618.
23. EBCTCG. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-1467.
24. Jordan V C, Gapstur S, Morrow M. Selective estrogen receptor modulation to reduce breast cancer risk, osteoporosis and coronary heart disease. J Natl Cancer Inst 2001; 93: 1449-1457.
25. Jakesz R, Hausmaninger H, Kubista E, Gnant M, Menzel C, Bauernhofer T, Seifert M, Haider M, Mlineritsch B, Steindorfer P, Kwasny W, Fridrik M, Steger G, Wette V, Samonigg H. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: Evidence for the superiority of treatment with endocrine blockade in remenopausal patients with hormone-responsive breast cancer - Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 2002; 15: 4621-4627.
26. Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes J C, de Matteis A, Stewart A, Eiermann W, Szakolczai I, Palmer M, Schumacher M, Geberth M, Lisboa B, Ellis J D. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the zoladex early breast cancer research association study. J Clin Oncol 2002; 15: 4628-4635.
27. Kvinnsland S, Anker G, Dirix L Y, Bonneterre J, Prove A M, Wilking N, Lobelle J P, Mariani O, di Salle E, Polli A, Massimini G. High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment. Eur J Cancer 2000; 36: 976-982.
28. Ellis M J, Coop A, Singh B, Mauriac L, Llambert F, Cussac A, Janicke F, Miller W R, Evans D B, Dugan M, Brady C, Quebe-Fehling E, Borgs M. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/or ErbB-2 positive estrogen receptor positive primary breast cancer: evidence from a phase III study. J Clin Oncol 2001; 19: 3808-3816.
29. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom H P, Janicke F, Pluzanska A, Dank M, Becquart D, Bapsy P P, Salminen E, Snyder R, Lassus M, Verbeek J A, Staffler B, Chaudri-Ross H A, Dugan M. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596-2606.
30. Nabholtz J M. Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000; 18: 3758-3767.
31. Bonneterre J, Thurlimann B, Robertson J F, Krzakowski M, Mauriac L, Koralewski P, Vergote I, Webster A, Steinberg M, von Euler M. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000; 18: 3748-3757.
32. The ATAC Trialist Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 2002; 359: 2131-2139.
33. Wakeling A E, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991; 51: 3867-3973.
34. Wijayaratne A L, McDonnell D P. The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem 2001; 276: 35684-35692.
35. Osborne C K, Pippen J, Jones S E, Parker L M, Ellis M, Come S, Gertler S Z, May J T, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002; 20: 3386-3395.
36. Howell A, Robertson J F R, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg U R, Vergot I, Erikstein B, Webster A, Morris C. Fulvestrant, formerly ICI 182, 780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002: 20: 3396-3403.
37. Fisher B, Costantino J P, Wickerham D L, Redmond C K, Kavanah M, Cronin W M, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-1388.
38. Ettinger B, Black D M, Mitlak B H, Knickerbocker R K, Nickelsen T, Genant H K, Christiansen C, Delmas P D, Zanchetta J R, Stakkestad J, Gluer C C, Krueger K, Cohen F J, Eckert S, Ensrud K E, Avioli L V, Lips P, Cummings S R. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [see comments]. JAMA 1999; 282: 637-645.
39. Lerner L J, Jordan V C. Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture. Cancer Res 1990; 50: 4177-4789.
40. Cummings S R, Eckert S, Krueger K A, Grady D, Powles T J, Cauley J A, Norton L, Nickelsen T, Bjarnason N H, Morrow M, Lippman M E, Black D, Glusman J E, Costa A, Jordan V C. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999; 281: 2189-2197.
41. Cauley J A, Norton L, Lippman M E, Eckert S, Krueger K A, Purdic D W, Farrerons J, Karasik A, Mellstrom D, Ng K W, Stephan J J, Powles T J, Morrow M, Costa A, Silfen S L, Walls E L, Schmitt H, Muchmore D B, Jordan V C. Continued breast cancer rusk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat 2001; 65(2): 125-134.
42. Brzozowski A M, Pike A C, Dauter Z, Hubbard R E, Bonn T, Engstrom O, Ohman L, Greene G L, Gustafsson J A, Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997; 389: 753-758.
43. Shiau A K, Barstad D, Loria P M, Cheng L, Kushner P J, Agard D A, Greene G L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998; 95: 927-937.
44. MacGregor Schafer J, Liu H, Bentrem D J, Zapf J W, Jordan V C. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. Cancer Res 2000; 60: 5097-5105.
45. Liu H, Lee E S, De Los Reyes A, Zapf J W, Jordan V C. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex. Cancer Res 200 1; 61: 3632-3639.
46. Bentrem D, Dardes R, Liu H, MacGregor-Schafer J, Zapf J, Jordan V. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen. Endocrinology 2001; 142: 838-846.
47. Liu H, Park W, Bentrem D, McKian K P, De Los Reyes A, MacGregor Schafer J, Zapt J, Jordan V C. Structure-function relationships of the raloxifene-estrogen receptor alpha complex for regulating transforming growth factor alpha expression in breast cancer cells. J Biol Chem 2002; 277: 9189-9198.
48. Pearce S T, Liu H, Jordan V C. Modulation of ER function and stability by tamoxifen and a critical amino acid D538 in helix 12. J Biol Chem 2003; 278: 7630-7638.
49. Newman S P, Bates N P, Vernimmen D, Parker M G, Hurst H C. Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer. Oncogene 2000; 19: 490-497.
50. Font de Mora J, Brown M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 2000; 20: 5041-5047.
51. List H-J, Lauritsen K J, Reiter R, Powers C, Wellstein A, Riegel A T. Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells. J Biol Chem 2001; 276: 23763-23768.
52. Lauritsen K J, List H-J, Reiter R, Wellstein A, Riegel A T. A role for TGF-beta in estrogen and retinoid mediated regulation of the nuclear receptor coactivator AIB1 in MCF-7 breast cancer cells. Oncogene 2002; 21: 7147-7155.
53. Knabbe C, Lippman M E, Wakefield L M, Flanders K C, Kasid A, Derynck R, Dickson RB. Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987; 48: 417-428.
54. Butta A, MacLennan K, Flanders K C, Sacks N P, Smith I, McKinna A, Dowsett M, Wakefield L M, Sporn M B, Baum M. Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 1992; 52: 4261-4264.
55. Osborne C K, Bardou V, Hopp T A, Chamness G C, Hilsenbeck S G, Fuqua S A, Wong J, Allred D C, Clark G, Schiff R. Role of the estrogen receptor coactivator AIB1 (SRC3) and HER2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003; 95: 353-361.
56. Osborne C K, Coronado-Heinsohn E B, Hilsenbeck S G, McCue B L, Wakeling A E, McClelland R A, Manning D L, Nicholson R I. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995; 87: 746-750.
57. Lee E S, Schafer J M, Yao K, England G, O'Regan R M, De Los Reyes A, Jordan V C. Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182, 780 in tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 2000; 6: 4893-4899.
58. Yao K, Lee E S. Bentrem D J, England G, Schafer J I, O'Regan R M, Jordan V C. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice [in process citation]. Clin Cancer Res 2000; 6: 2028-2036.
59. Howell A, Dodwell D J, Anderson H, Redford J. Response after withdrawal of tamoxifen and progestogens in advanced breast cancer [see comments]. Ann Oncol 1992; 3: 611-617.
60. Gottardis M M, Robinson S P, Satyaswaroop P G, Jordan V C. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 1988; 48: 812-815.
61. Fisher B, Costantino J P, Redmond C K, Fisher E R, Wickerham D L, Cronin W M. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86: 527-537.
62. Osborne C K, Hobbs K, Clark G M. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 1985; 45: 584-590.
63. Gottardis M M. Robinson S P, Jordan V C. Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem 1988; 30: 311-314.
64. Dardes R C, MacGregor Schafer J, Timm Pearce S, Osipo C, Chen B, Jordan V C. Regulation of estrogen target genes and growth by selective estrogen receptor modulators in endometrial cancer cells. Gynecol Oncol 2002; 85: 498-506.
65. Gottardis M M, Jordan V C. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 1988; 48: 5183-5187.
66. Osborne C K, Coronado E B, Robinson J P. Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol 1987; 23: 1189-1196.
67. MacGregor Schafer J I, Lee E-S, O'Regan R M, de los Reyes A, Jordan V C. Rapid development of tamoxifen stimulated mutat p53 tumors (T47D) in athymic mice. Clin Cancer Res 2000; 6: 4373-4380.
68. O'Regan R M, Gajdos C, Dardes R C, De Los Reyes A, Park W, Rademaker A W, Jordan V C. Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice. J Natl Cancer Inst 2002; 94: 274-283.
69. Wolf D M, Jordan V C. A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy. Recent Results Cancer Res 1993; 127: 23-33.
70. Lonning P E, Taylor P D, Anker G, Iddon J. Wie L, Jorgensen L M, Mella O, Howell A. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 2001; 67: 111-116.
71. Song R X, Mor G, Naftolin F, McPherson R A, Song J, Zhang Z, Yue W, Wang J, Santen R J. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst 2001; 93: 1714-1723.
72. Liu H, Lee E-S, Gajdos C, Pearce S T, Chen B, Osipo C, Loweth J, McKian K, De Los Reyes A, Wing L, Jordan V C. Dual effects on cell proliferation and apoptosis of 17-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. Proceeding of the American Association of Cancer Research 2003; 44: Abstract# 4910.
73. Osipo C, Gajdos C, Liu H, Jordan V C. 17 beta-estradiol causes rapid tumor regression of tamoxifen-stimulated breast cancer in vivo by induction of Fas and suppression of NF-kB. Proceeding of the American Association of Cancer Research 2003; 44: Abstract# 4911.
74. Jordan V C. Antiestrogens, selective estrogen receptor modulators as multifunctional medicines Part I: Receptor Interactions. J Med Chem 2003; 46: 883-908.